News

September 7, 2017

Anavex Obtains U.S. Patent on Combinations of Anavex 2-73 and Donepezil to Protect Nerve Cells

The U.S. Patent and Trademark Office has granted Anavex Life Sciences a patent covering nerve protection treatments that combine Anavex 2-73 and donepezil. The patent is titled “ANAVEX 2-73 ... Read more

September 6, 2017

Daily-living Virtual Assistant That Reads Emotions Being Developed for Alzheimer’s Patients

News

Canadian researchers are working on the creation of a virtual assistant that could help people with Alzheimer’s disease do a better job of managing their daily lives. A key ... Read more

September 5, 2017

First Phase 1 Trial Participant Receives HTL0016878, Heptares’ Therapy for Cognitive Impairment in Alzheimer’s

News

The first participant in a Phase 1 clinical trial of HTL0016878 as a treatment for cognitive impairment in Alzheimer’s disease is receiving the therapy, according to its developer, Heptares Therapeutics. Heptares, ... Read more

September 1, 2017September 1, 2017

2 Separate Studies Show How Rare Mutation on TREM2 Gene Contributes to Alzheimer’s

News

Researchers of two independent studies have discovered how a specific mutation on the TREM2 gene contributes to the development and progression of Alzheimer’s disease, findings that shed light on the role of ... Read more

August 31, 2017September 8, 2017

Arizona Researchers Develop Blood Test to Diagnose Early Alzheimer’s Disease

News

Alzheimer’s disease leaves traces in the white blood cells of its patients that could be used to diagnose the disease. So says a study by researchers at Arizona State ... Read more

August 30, 2017

A.I., Big Data Project Predicts Dementia 2 Years Before Symptoms Onset, Researchers Show

News

New artificial intelligence (AI) research conducted at McGill University in Canada suggests that doctors may soon have the tools to predict an individual’s likelihood of developing dementia several years ... Read more

August 29, 2017August 30, 2017

Aducanumab Lowers Amyloid Plaque Associated with Alzheimer’s, Extension Trial Shows

News

Aducanumab reduced deposits of the amyloid plaque associated with Alzheimer’s disease in the brains of early-stage patients who took part in a three-year extension trial, Biogen reports. After the study ... Read more

August 28, 2017

Pathway Linking Inflammation to Cellular Processes May Provide Target for Alzheimer’s, Study Suggests

News

The link between brain inflammation, cell growth and division, and neuronal death could provide a target to treat Alzheimer’s and other neurodegenerative disease, research suggests. The study, “LPS-induced inflammatory response ... Read more

August 25, 2017August 25, 2017

Caprion Teaming Up with Biomarkers Consortium to Study if Biomarkers Can Track Alzheimer’s Progression

News

Caprion Biosciences Inc. is partnering with a public-private organization known as the Biomarkers Consortium to study whether biomarkers can be used to track changes in early Alzheimer’s disease progression. ... Read more